Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02083926 · ClinicalTrials.gov registry record · Early Phase 1
Ketamine Infusion for Social Anxiety Disorder
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT02083926 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 18 participants.
The verdict
NCT02083926, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
* Social Anxiety Disorder (SAD) is common and causes significant impairment. * First-line treatments for Social Anxiety Disorder are only partially effective. Many SAD patients experience little or inadequate symptom relief with available treatments. * Ketamine is a potent NMDA receptor antagonist. Ketamine represents an agent with a potentially novel mechanism of action for the treatment of anxiety disorders. * Ketamine has demonstrated efficacy in the treatment of psychiatric disorders closely related to Social Anxiety Disorder including Major Depression, Bipolar Depression and possibly Obsessive-Compulsive Disorder. Ketamine represents the possibility to provide rapid symptom relief to patients with SAD and may provide the mechanism for future drug development to treat SAD more rapidly and effectively.
Interventions
- DRUG Ketamine
- OTHER Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-01-02 |
| Est. Completion | 2016-09-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02083926
The ClinicalTrials.gov registry entry for NCT02083926 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT02083926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02083926 about?
NCT02083926 is a clinical study titled "Ketamine Infusion for Social Anxiety Disorder". * Social Anxiety Disorder (SAD) is common and causes significant impairment. * First-line treatments for Social Anxiety Disorder are only partially effective. Many SAD patients experience little or inadequate symptom relief with available treatments. * Ketamine is a potent NMDA receptor antagonist. ...
What is the current status of trial NCT02083926?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2015-01-02. Estimated completion is 2016-09-27.
What interventions are being tested in trial NCT02083926?
The interventions under investigation include: Ketamine (DRUG), Saline (OTHER).
Who is sponsoring clinical trial NCT02083926?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.